Pauline Pelletier

I'll research this attorney's professional background.

Pauline M. Pelletier — Senior Counsel, Intellectual Property & Litigation, Amgen Inc. (in-house); previously Director, Sterne, Kessler, Goldstein & Fox PLLC (Trial & Appellate Practice Group).

Specialty / focus. Her practice centers on patent litigation in the federal district courts and the U.S. International Trade Commission, post-grant proceedings (IPR/PGR) and reexaminations at the USPTO, and Federal Circuit appeals. Sterne Kessler's published bios describe her client base as life sciences, electronics, and automotive companies, with additional counseling work in regulated/emerging areas such as cannabinoid therapeutics, reflecting a technical background in bioinformatics/biotechnology. The single tracked matter is a biologics (BPCIA) pharmaceutical case, consistent with that life-sciences emphasis.

Side preference. The tracked data is thin — one appearance, on the defendant side, in an in-house capacity. Her litigation record otherwise is predominantly defense-side representation of operating companies (Teva, Luminara, Amgen), rather than plaintiff-side assertion for NPEs/PAEs; no NPE/PAE plaintiff work appears in the sources reviewed.

Firm context. She spent the bulk of her litigation career at Sterne Kessler, joining as an associate, clerking for then-Chief Judge Randall R. Rader of the U.S. Court of Appeals for the Federal Circuit, returning to the firm, and becoming a director (listed from 2019). She later moved in-house to Amgen as Senior Counsel, IP & Litigation. (The firm-history details come from firm/third-party bios and a Johns Hopkins pre-law interview; the Amgen title is sourced from a third-party org chart, not an Amgen press release, so treat the exact title as unconfirmed.)

Notable matters. The tracked case is Regeneron Pharmaceuticals, Inc. v. Amgen Inc., part of the consolidated aflibercept (Eylea/Pavblu) BPCIA MDL in the N.D. W. Va. Regeneron asserted U.S. Patent No. 12,331,099 against Amgen's biosimilar ABP 938/Pavblu; Amgen countersued and asserted inequitable conduct, patent misuse, unclean hands, antitrust/Walker Process and California UCL claims plus prosecution laches. In July 2026 the court dismissed most of Amgen's counterclaims and defenses, allowing only the prosecution-laches theory to proceed; the Federal Circuit earlier affirmed denial of Regeneron's preliminary injunction against Amgen (relying on the absence of a separate buffer in Amgen's formulation). At Sterne Kessler, she was part of the team (with J.C. Rozendaal, Michael Joffre, and Trey Powers) representing Teva in the Saint Regis Mohawk Tribe/Allergan v. Mylan/Teva/Akorn litigation, which invalidated all patents in suit after a bench trial and earned Managing Intellectual Property's 2019 "Impact Case of the Year" award. She also appeared as counsel in PTAB/ITC matters for Luminara.

PTAB / IPR. Her Sterne Kessler practice included regular post-grant work — she appeared at IPR oral hearings and co-authored multiple PTAB/Federal Circuit analyses (including on the Microsoft v. Proxyconn reversal and PTAB burden-of-persuasion and time-bar issues). No IPR/PGR filings are reflected in the tracked case list itself.

Bar / education. J.D., cum laude, University of Maryland Francis King Carey School of Law (2012); undergraduate degree from Johns Hopkins University, with subsequent graduate study in bioinformatics/biotechnology there. Admitted to practice in the District of Columbia (bar admission details not independently verified here).